PerssonPD. Contrast medium induced nephropathy. Nephrol Dial Transplant. 2005; 20(Suppl 1): ii.
2.
NashKHafeezAHouS. Hospital-acquired renal insufficiency. Am J Kidney Dis.2002; 39: 930–936.
3.
ThomsenHSMorcosSK. Contrast media and the kidney: European Society of Urogential Radiology (ESUR) guidelines. Br J Radiol.2003; 76: 513–518.
4.
LasserECLyonSGBerryCC. Reports on contrast media reactions: Analysis of data from reports to the US Food and Drug Administration. Radiology. 1997; 203: 605–610.
5.
McCulloughPAWolynRRocherLL. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med.1997; 103: 368–375.
6.
RashidSTSalmanMMyintF. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: A randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg.2004; 40: 1136–1141.
7.
RihalCSTextorSCGrillDE. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002; 105: 2259–2264.
8.
TumlinJStaculFAdamA. Pathophysiology of contrast-induced nephropathy. Am J Cardiol.2006; 98(Suppl 1): 14–20.
MorrisTWKatzbergRWFischerHW. A comparison of the hemodynamic responses to metrizamide and meglumine/sodium diatrizoate in canine renal angiography. Invest Radiol.1978; 13: 74–78.
HallerCHizohI. The cytotoxicity of iodinated radiocontrast agents on renal cells in vitro. Invest Radiol.2004; 39: 149–154.
13.
BartholomewBAHarjaiKJDukkipatiS. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol.2004; 93: 1515–1519.
14.
FreemanRVO'DonnellMShareD. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol.2002; 90: 1068–1073.
15.
IakovouIDangasGMehranR. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol.2003; 15: 18–22.
NikolskyEAymongEDDangasG. Radiocontrast nephropathy: Identifying the high-risk patient and the implications of exacerbating renal function. Rev Cardiovasc Med.2003; 4(Suppl 1): S7–S14.
18.
HallKAWongRWHunterGC. Contrast-induced nephrotoxicity: The effects of vasodilator therapy. J Surg Res.1992; 53: 317–320.
19.
LameireNAdamABeckerCR. Baseline renal function screening. Am J Cardiol.2006; 98(Suppl 1): 21–26.
20.
MehranRNikolskyE. Contrast-induced nephropathy: Definition, epidemiology, and patients at risk. Kidney Int.2006; 100(Suppl): S11–S15.
21.
NikolskyEMehranRTurcotD. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol.2004; 94: 300–305.
22.
BernsAS. Nephrotoxicity of contrast media. Kidney Int.1989; 36: 730–740.
23.
GussenhovenMJRavensbergenJvan BockelJH. Renal dysfunction after angiography; a risk factor analysis in patients with peripheral vascular disease. J Cardiovasc Surg.1991; 32: 81–86.
24.
CirilloMLaurenziMManciniM. Low glomerular filtration in the population: Prevalence, associated disorders, and awareness. Kidney Int.2006; 70: 800–806.
25.
MeschiMDetrenisSMusiniS. Facts and fallacies concerning the prevention of contrast medium-induced nephropathy. Crit Care Med.2006; 34: 2060–2068.
26.
VlietstraRENunnCMNarvarteJ. Contrast nephropathy after coronary angioplasty in chronic renal insufficiency. Am Heart J.1996; 132: 1049–1050.
27.
ManskeCLSprafkaJMStronyJT. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med.1990; 89: 615–620.
28.
BarrettBJCarlisleEJ. Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology. 1993; 188: 171–178.
29.
RudnickMRGoldfarbSWexlerL. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: A randomized trial. Kidney Int.1995; 47: 254–261.
30.
AspelinPAubryPFransonSG. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med.2003; 348: 491–499.
31.
CarraroMMalalanFAntonioneR. Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: A double-blind, randomized clinical trial. Eur Radiol.1998; 8: 144–147.
32.
JoSHYounTJKooBK. Renal toxicity evaluation and comparison between Visipaque (iodixanol) and Hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: The RECOVER study, a randomized controlled trial. J Am Coll Cardiol.2006; 48: 924–930.
MehranRAymongEDNikolskyE. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol.2004; 44: 1393–1399.
36.
CochranSTWongWSRoeDJ. Predicting angiography-induced acute renal function impairment: Clinical risk model. AJR Am J Roentgenol.1983; 141: 1027–1033.
37.
McCulloughPAAdamABeckerCR. Risk prediction of contrast-induced nephropathy. Am J Cardiol.2006; 98(Suppl): 27–36.
38.
McCulloughPAStaculFDavidsonC. Overview. Am J Cardiol.2006; 98(Suppl 1): 2–4.
39.
SolomonRDerayG. How to prevent contrast-induced nephropathy and manage risk patients: Practical recommendations. Kidney Int.2006; 100(Suppl): S51–53.
40.
StaculFAdamABeckerCR. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol.2006; 98(Suppl 1): 59–77.
TaylorAJHotchkissDMorseRW. PREPARED: Preparation for Angiography in Renal Dysfunction: A randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest. 1998; 114: 1570–1574.
43.
TrivediHSMooreHNasrS. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract.2003; 93: C29–34.
44.
DussolBMorangeSLoundounA. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant. 2006; 21: 2120–2126.
45.
BaderBDBergerEDHeedeMB. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity?Clin Nephrol.2004; 62: 1–7.
46.
KrasuskiRABeardBMGeoghaganJD. Optimal timing of hydration to erase contrast-associated nephropathy: The OTHER CAN study. J Invasive Cardiol.2003; 15: 699–702.
47.
MuellerCBuerkleGBuettnerHJ. Prevention of contrast media-associated nephropathy: Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med.2002; 162: 329–336.
48.
SolomonRWernerCMannD. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med.1994; 331: 1416–1420.
49.
MertenGJBurgessWPGrayLV. Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA. 2004; 291: 2328–2334.
50.
MuellerC. Prevention of contrast-induced nephropathy with volume supplementation. Kidney Int.2006; 100(Suppl): S16–19.
51.
ShammasNWKapalisMJHarrisM. Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures. J Invasive Cardiol.2001; 13: 738–740.
52.
AbizaidASClarkCEMintzGS. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol.1999; 83: 260–263.
53.
TsaoCRLiuTJChenFC. Intravenous aminophylline provides no additional renal protection in patient with severe atherosclerotic renal artery stenosis treated by delicate percutaneous renal intervention. Int J Cardiol.2006; 110: 122–124.
54.
BagshawSMGhaliWA. Theophylline for prevention of contrast induced nephropathy: A systematic review and meta-analysis. Arch Intern Med.2005; 165: 1087–1093.
SpargiasKAlexopoulosEKyrzopoulosS. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004; 110: 2837–2842.
57.
IsenbargerDWKentSMO'MalleyPG. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol.2003; 92: 1454–1458.
58.
BirckRKrzossokSMarkowetzF. Acetylcysteine for prevention of contrast nephropathy: Meta-analysis. Lancet. 2003; 362: 598–603.
59.
AlonsoALauJJaberBL. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: A meta-analysis of randomized controlled trials. Am J Kidney Dis.2004; 43: 1–9.
60.
NallamothouBShojaniaKGSaintS. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med.2004; 117: 938–947.
61.
KshirsagarAVPooleCMottlA. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: A meta-analysis of prospective controlled trials. J Am Soc Nephrol.2004; 15: 761–769.
62.
ZaglerAAzadpourMMercadoC. N-acetylcysteine and contrast-induced nephropathy: A meta-analysis of 13 randomized trials. Am Heart J.2006; 151: 140–145.
63.
SandhuCBelliAMOliveiraDB. The role of N-acetylcysteine in the prevention of contrast-induced nephrotoxicity. Cardiovasc Intervent Radiol.2006; 29: 344–347.
64.
MooreNMLapsleyMNordenAG. Does N-acetylcysteine prevent contrast induced nephropathy during endovascular AAA repair? A randomised controlled pilot study. J Endovasc Ther.2006; 13: 660–666.
65.
WeinsteinJMHeymanSBrezisM. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron. 1992; 62: 413–415.
66.
KhanalSAttallahNSmithDE. Statin therapy reduces contrast-induced nephropathy: An analysis of contemporary percutaneous interventions. Am J Med.2005; 118: 843–849.
67.
AttallahNYassineLMusialJ. The potential role of statins in contrast nephropathy. Clin Nephrol.2004; 62: 273–278.
68.
HuberWJeschkeBKreymannB. Haemodialysis for the prevention of contrast-induced nephropathy: Outcome of 31 patients with severely impaired renal function, comparison with patients at similar risk and review. Invest Radiol.2002; 37: 471–481.
69.
FrankHWernerDLorussoV. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure. Clin Nephrol.2003; 60: 176–182.
70.
MarenziGMaranaILauriG. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med.2003; 349: 1333–1340.
71.
AlsacJMZarinsCKHeikkinenMA. The impact of aortic endografts on renal function. J Vasc Surg.2005; 41: 926–930.
72.
SurowiecSMDaviesMGFegleyAJ. Relationship of proximal fixation to postoperative renal dysfunction in patients with normal serum creatinine concentration. J Vasc Surg.2004; 39: 804–810.
73.
ArkoFRFilisKAHeikkinenMA. Duplex scanning after endovascular aneurysm repair: An alternative to computed tomography. Semin Vasc Surg.2004; 17: 161–165.
74.
SunZ. Diagnostic value of color duplex ultrasonography in the follow-up of endovascular repair of abdominal aortic aneurysm. J Vasc Interv Radiol.2006; 17: 759–764.
75.
AscherEMarksNASchutzerRW. Duplex-guided balloon angioplasty and stenting for femoropopliteal arterial occlusive disease: An alternative in patients with renal insufficiency. J Vasc Surg.2005; 42: 1108–1113.
76.
AscherEMarksNAHingoraniAP. Duplex-guided balloon angioplasty and subintimal dissection of infrapopliteal arteries: Early results with a new approach to avoid radiation exposure and contrast material. J Vasc Surg.2005; 42: 1114–1121.
77.
ShawDRKesselDO. The current status of the use of carbon dioxide in diagnostic and interventional angiographic procedures. Cardiovasc Intervent Radiol.2006; 29: 323–331.
78.
NeschisDGFairmanRM. Magnetic resonance imaging for planning aortic endograft procedures. Semin Vasc Surg.2004; 17: 135–143.
79.
OzturkCGuttmanMMcVeighER. Magnetic resonance imaging-guided vascular interventions. Top Magn Reson Imaging. 2005; 16: 369–381.
80.
CockcroftDWGaultMH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31–41.
81.
NymanUElmstahlBLeanderP. Are gadolinium-based contrast media really safer than iodinated media for digital subtraction angiography in patients with azotemia?Radiology. 2002; 223: 311–319.
